Please assess the completion status of the following clinical trial:

Trial Title: Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. History of acute myeloid leukaemia (initially diagnosed by presence of 20% or more blast cells with myeloid or monocytic differentiation confirmed by flow cytometry in peripheral blood or bone marrow)~2. Relapsed or refractory AML~   1. AML relapse after intensive chemotherapy OR~  2. AML relapse after allogeneic HCT OR~  3. AML progression on low intensity therapy (low dose cytarabine, 5-azacytidine or decitabine) OR~  4. No response to at least 4 cycles of low intensity therapy~  5. AML refractory to 2 cycles of induction chemotherapy~3. Presence of \> 5% of blasts in bone marrow or peripheral blood smear~4. Patient not eligible for or does not consent to high dose salvage chemotherapy and/or allogeneic Haematopoietic Cell Transplantation (HCT)~5. Considered suitable for lymphodepleting chemotherapy~6. Age 18 years up to the age of 70 (≤ 70)~7. Life expectancy of at least 3 months~8. Karnofsky performance status ≥ 50%~9. Available related HLA-haploidentical or HLA-matched donor~10. Ability to be off systemic prednisone and other immunosuppressive drugs for at least 3 days prior to γδ T cells product infusion. Maintenance replacement steroid is allowed.~11. Patient able to understand and sign written informed consent~Exclusion Criteria:~1. Uncontrolled infections~2. Renal insufficiency: creatinine \> 180 μmol/L or on dialysis~3. Heart failure: EF \< 40%~4. Respiratory insufficiency: oxygen therapy required at inclusion in the study~5. Significant liver impairment: bilirubin \> 50 μmol/L, AST or ALT \> 4 times normal upper limit~6. Treatment with bisphosphonates (2 months before start)~7. Active autoimmune disease or GvHD~8. Pregnant or breastfeeding~9. Patient of fertile age not using two-barrier method of birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): After inclusion, patients will receive conditioning chemotherapy consisting of non-investigational medicinal products (non-IMPs): fludarabine 25 mg/m2 from day -6 until day -2 (inclusive) and cyclophosphamide 500 mg/m2 on days -6 and -5.~Subsequently, patients in will be dosed with investigational medicinal product (IMP) OmnImmune® on day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).